On July 11, 2023, Crossbow Therapeutics, Inc. closed the transaction. The company has issued 32,639,874 series A preferred shares at an issue price of $1.3 per share for the gross proceeds of $42,431,836.2 in its second and final tranche, the company has issued total 61,538,462 series A preferred shares for gross proceeds of $80,000,000.6 in the transaction. The transaction was co-led by MPM Asset Management, L.L.C., and Pfizer Venture Investments LLC, and included participation other new investors, Polaris Venture Partners, Inc., BVF Partners L.P., Eli Lilly and Company, Mirae Asset Venture Investment Co., Ltd., and Mirae Asset Capital Co., Ltd. The round is raised at a post-money valuation of $112,545,580.